Astellas (4503) - PROSPER Data Revives Value Story
For a drug that was targeted to hit US$6~8bil in sales, last year’s US$2.3bil revenue figure for Xtandi was decidedly below par. With the start of...
314 Views
Surveying The Biosimilar Battlefield
The biosimilar market has been of particular interest to us in light of the high expectations set for Samsung Biologics Co., Ltd (207940 KS) Â and...
890 Views
Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
347 Views
JNJ's REMICADE Holds: PFE's Results To Confirm
Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (reference product for...
671 Views
Celltrion Healthcare IPO Part 2 - 3 Key Issues
Celltrion Healthcare (091990 KS) will start meeting local investors from June 26. As for the overseas IPO deal roadshow, the company will start...
530 Views